The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics

Journal of Controlled Release

Volumn 144, Issue 1, 2010, Pages 10-16

  Chae, Su Young ^a   Choi, Yang Gyu ^a   Son, Sohee ^a   Jung, Sung Youb ^a   Lee, Doo Sung ^a   Lee, Kang Choon ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Conjugation; Exendin 4; Fatty acid; GLP 1; Long acting; Type 2 diabetes

Indexed keywords

ANTIDIABETIC; ANTIDIABETIC ACTIVITY; BIOLOGICAL ACTIVITIES; DIABETIC MICE; EXENDIN-4; IN-VITRO; IN-VIVO; INSULINOTROPIC ACTIVITY; LAURIC ACID; LYSINE RESIDUES; MEAN RESIDENCE TIME; NORMOGLYCEMIA; PALMITIC ACID; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC STUDIES; RECEPTOR ACTIVATION; RECEPTOR BINDING; TYPE-2 DIABETES;

ACIDS; AMINO ACIDS; BINDING ENERGY; DRUG PRODUCTS; PHARMACOKINETICS;

FATTY ACIDS;

EXENDIN 4; EXENDIN 4[12 LYSINE]LAURIC ACID; EXENDIN 4[12 LYSINE]PALMITIC ACID; EXENDIN 4[12,27 LYSINE]LAURIC ACID; EXENDIN 4[12,27 LYSINE]PALMITIC ACID; EXENDIN 4[27 LYSINE]LAURIC ACID; EXENDIN 4[27 LYSINE]PALMITIC ACID; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; MALE; MEAN RESIDENCE TIME; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIGENS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GLUCAGON-LIKE PEPTIDE 1; HALF-LIFE; HYPOGLYCEMIC AGENTS; LYSINE; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PALMITIC ACID; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VENOMS;

EID: 77953809853     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.01.024     Document Type: Article

References (29)

1. Kieffer T.J., Habener J.F. The glucagon-like peptide. Endocr. Rev. 1999, 20:876-913.
2. Drucker D.J. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 2007, 117:24-32.
3. Meier J.J., Nauck M.A. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab. Res. Rev. 2005, 21:91-117.
4. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
5. Kieffer T.J., McIntosh C.H.S., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
6. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue from Heloderma suspectum venom. J. Biol. Chem. 1992, 267:7402-7405.
7. Kendall D.M., Riddle M.C., Rosenstock J., Zhuang D., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
8. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., Zychma M., Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
9. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., Taylor K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
10. Simonsen L., Holst J.J., Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetized pigs. Diabetologia 2006, 49:706-712.
11. BYETTA prescribing information [article online, revised at June 2008], URL: http://pi.lilly.com/us/byetta-pi.pdf.
12. Lee S., Youn Y.S., Lee S.H., Byun Y., Lee K.C. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 2006, 49:1608-1611.
13. Zhou J., Cai Z.H., Li L., Kou C., Gao Y.F. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris. Eur. J. Pharm. Biopharm. 2009, 72:412-417.
14. Pan C.Q., Buxton J.M., Yung S.L., Tom I., Yang L., Chen H., MacDougall M., Bell A., Claus T.H., Clairmont K.B., Whelan J.P. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 2006, 281:12506-12515.
15. Kim J.G., Baggio L.L., Bridon D.P., Castaigne J.P., Robitaille M.F., Jette L., Benquet C., Drucker D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52:751-759.
16. Huang Y.S., Chen Z., Chen Y.Q., Ma G.C., Shan J.F., Liu W., Zhou L.F. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 2008, 14:588-595.
17. Rolin B., Larsen M.O., Gotfredsen C.F., Deacon C.F., Carr R.D., Wilken M., Knudsen L.B. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E745-E752.
18. Madsen K., Knudsen L.B., Agersoe H., Nielsen P.F., Thogersen H., Wilken M., Johansen N.L. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J. Med. Chem. 2007, 50:6126-6132.
19. 37PAL): Novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J. Med. Chem. 2006, 49:1047-1054.
20. Jonassen I., Havelund S., Ribel U., Plum A., Loftager M., Hoeg-Jensen T., Volund A., Markussen J. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm. Res. 2006, 23:49-55.
21. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem. 1993, 268:19650-19655.
22. Al-Sabah S., Donnelly D. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br. J. Pharmacol. 2003, 140:339-346.
23. Jin C.H., Chae S.Y., Son S., Kim T.H., Um K.A., Youn Y.S., Lee S., Lee K.C. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4 displays improved hypoglycemic effect in db/db mice. J. Control. Release 2009, 133:172-177.
24. Chae S.Y., Jin C.H., Shin H.J., Youn Y.S., Lee S., Lee K.C. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery. Bioconjug. Chem. 2008, 19:334-341.
25. Chae S.Y., Chun Y.G., Lee S., Jin C.H., Lee E.S., Lee K.C., Youn Y.S. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controller. J. Pharm. Sci. 2009, 98:1556-1567.
26. Son S., Chae S.Y., Kim C.W., Choi Y.G., Jung S.Y., Lee S., Lee K.C. Preparation and structural, biochemical and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. J. Med. Chem. 2009, 52:6889-6896.
27. Chae S.Y., Jin C.H., Shin J.H., Son S., Kim T.H., Lee S., Youn Y.S., Byun Y., Lee M.S., Lee K.C. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J. Control. Release 2010, 142:206-213.
28. Kim K., Kwon S., Park J.H., Chung H., Jeong S.Y., Kwon I.C. Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. Biomacromolecules 2005, 6:1154-1158.
29. Chae S.Y., Son S., Lee M., Jang M.K., Nah J.W. Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. J. Control. Release 2005, 10:330-344.